Lumiracoxib is an amino acid that is phenylacetic acid that is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity. Among its listed roles, it functions as a non-steroidal anti-inflammatory drug and a cyclooxygenase 2 inhibitor. It is a monocarboxylic acid, an amino acid, an organochlorine compound, an organofluorine compound and a secondary amino compound. It is grouped under the following drug class(es): Cyclooxygenase‑2 (COX‑2) Inhibitors and Non-Steroidal Anti-Inflammatory Drugs (NSAID). Its therapeutic use is listed as antirheumatic agents. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include lumiracoxibum and Prexige. Its PubChem CID is 151166.
Lumiracoxib
| CAS No | 220991-20-8 |
|---|---|
| Molecular Formula | C15H13ClFNO2 |
| Molecular Weight | 293.72 g/mol |
| Synonyms | 2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Lumiracoxib is an amino acid that is phenylacetic acid that is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group.
The listed CAS number is 220991-20-8.
The listed molecular formula is C15H13ClFNO2.
The listed molecular weight is 293.72 g/mol.
2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid.
The source lists lumiracoxibum and Prexige.